Skip to main content
. Author manuscript; available in PMC: 2009 Aug 1.
Published in final edited form as: Mol Cancer Res. 2008 Aug;6(8):1356–1364. doi: 10.1158/1541-7786.MCR-08-0108

Figure 2. Primary MM cells display constitutive NF-κ B activity that is largely resistant to high concentrations of bortezomib.

Figure 2

(A) Representative mini-EMSA, using whole cell lysates from the indicated total cell numbers, fold-induction as determined by phosphoimager is labeled below the gel. (B) Analysis of percent proteasome inhibition by increasing doses of bortezomib in CD138+ cells obtained from two MM patients using Proteo-Glo (Biorad) assay. Basal proteasomal activity for each cell type is assigned as 100% activity. (C) EMSA analysis of lysates derived from CD138+ cells isolated from the indicated patients and then treated with 100nM bortezomib for 4 hours where indicated. Fold-change in NF-κ B activity corrected for Oct-1 DNA-binding is displayed below the gels. (D) Fold-change NF-κ B DNA-binding, as measured by phosphoimage quantification corrected for Oct-1 DNA-binding, induced by treatment with 4 hours 100nM bortezomib in CD138+ cells from the indicated MM patients.